A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of KK2223 in adult participants with relapsed or refractory peripheral T cell lymphoma (PTCL) or cutaneous T cell lymphoma (CTCL).
Adults (≥18 years) with confirmed T-cell lymphoma subtypes: PTCL (including noda... [+9]
Recent autologous or allogeneic transplant within 120 days before treatment; act... [+15]